Synapse Biomedical

Synapse Biomedical occupies a focused medical-device niche at the intersection of neurostimulation and respiratory care. Its core differentiation is diaphragm pacing: the NeuRx system combines implanted electrodes with an external pulse generator to stimulate and condition the diaphragm, rather than targeting the broader range of neurological indications served by general neuromodulation platforms. Its TransAeris System addresses a related but distinct clinical need—temporary stimulation intended to prevent or treat ventilator-induced diaphragm dysfunction. Synapse’s specialized focus and product set distinguish its offering, while larger medical-device companies may have broader portfolios and commercial reach. The company is privately held, has 11–50 employees in the reported size band, and has raised $3,103,358 across four rounds, with its latest recorded round in 2015.

Synapse Biomedical was founded in 2002 to commercialize the NeuRx Diaphragm Pacing System, developed from research at Case Western Reserve University and University Hospitals of Cleveland. Its funding history shows an early financing sequence: a $270,000 pre-seed round in 2006, $433,358 in 2010, $2.4 million in 2013, and a 2015 venture round with no amount disclosed. The reported total is $3,103,358 across four rounds, making the 2013 financing the largest round with a stated amount. The product portfolio extends beyond the implanted NeuRx system to include PermaLoc electrodes, an external pulse generator, a clinical station, and the temporary TransAeris system. A 2023 report noted FDA approval broadening access to the diaphragm pacing system, and Jason Fiest joined as Vice President of Quality & Regulatory in 2024. With no later financing date or quantified employee-growth trend available, the trajectory appears centered on specialized product development and regulated-market access rather than documented rapid expansion.